Press coverage about Celator Pharmaceuticals (NASDAQ:CPXX) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive press coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Celator Pharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.3171657141534 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

TRADEMARK VIOLATION WARNING: “Celator Pharmaceuticals (CPXX) Getting Somewhat Favorable Press Coverage, Report Finds” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was illegally copied and reposted in violation of United States & international trademark & copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/celator-pharmaceuticals-cpxx-getting-somewhat-favorable-press-coverage-report-finds/1634949.html.

About Celator Pharmaceuticals

Celator Pharmaceuticals, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company’s technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity.

Insider Buying and Selling by Quarter for Celator Pharmaceuticals (NASDAQ:CPXX)

Receive News & Ratings for Celator Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celator Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.